Eplar 25mg Tablet contains Eplerenone, a selective aldosterone receptor antagonist used primarily in the management of hypertension and heart failure. By competitively blocking aldosterone at mineralocorticoid receptors, Eplerenone reduces sodium and water retention, thereby decreasing blood volume and lowering blood pressure. It is particularly beneficial in patients with left ventricular dysfunction following myocardial infarction, as it has been shown to reduce morbidity and mortality. Eplar 25mg is indicated for use as adjunctive therapy in patients with essential hypertension and for the treatment of heart failure with reduced ejection fraction. The recommended dose varies based on clinical condition and patient response, with careful monitoring of serum potassium and renal function advised due to the risk of hyperkalemia. Contraindications include hyperkalemia, severe renal impairment, and hypersensitivity to the active ingredient. Common adverse effects may include dizziness, hyperkalemia, and gastrointestinal disturbances. Eplar 25mg should be used cautiously in patients with impaired hepatic function and those on concomitant potassium-sparing diuretics or potassium supplements. Regular follow-up and laboratory assessments are essential to optimize therapeutic outcomes and minimize potential risks associated with therapy.